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INTRODUCTION 
Hepatitis B (formerly  known  as “serum” hepatitis) is an acute 
systemic infection  with major pathology in the liver, caused by hepatitis 
B virus (HBV) and transmitted usually by the parenteral route. It is 
clinically characterised by a tendency to a long incubation period (6 
weeks to 6 months) and a protracted illness with a variety of outcomes. 
Usually, it is an acute self-limiting infection, which may be either 
subclinical or symptomatic. In approximately 5 to 15 per cent of cases, 
HBV infection fails to resolve and the affected individuals then become 
persistent carriers of the virus.  Persistent HBV infection may causes, 
progressive liver disease including chronic active hepatitis and 
hepatocellular carcinoma.  There is also evidence of a-close association 
between hepatitis B and primary liver cancer Hepatitis B virus can form a 
dangerous alliance with delta virus and produce a new form of virulent 
hepatitis which is considered to be a widespread threat for much of the 
world. 
Hepatitis B is endemic throughout the world, especially in tropical 
and developing countries and also in some regions of Europe. Its 
prevalence varies from country to country and depends upon a complex 
 
 
 
mix of behavioural, environmental and host factors. In general, it is 
lowest in countries or areas with high standards of living. 
The HBV infection is a global problem, with 66 percent of all the 
world's population living in areas where there are high levels of infection. 
More than 2 billion people worldwide have evidence of past or 
current HBV infection and 350 million are chronic carriers of the virus, 
which is harboured in the liver, the virus causes 60-80 per cent of all 
primary liver cancer, which is one of the three top causes of cancer death 
in East the Pacific Basin and Sub -Saharan Africa.. 
Infection with HBV is a major cause of morbidity and mortality in 
the SEAR.   More than One-third of the population has been infected with 
HBV and it is estimated that there are 80 million HBV carriers (about 6% 
of the total population). Many are lifelong carriers, although not all are 
infectious, and some will clear the virus after intervals varying from 
many months to years. Between 5 percent and 10 percent of adults and up 
to 80 per cent .of infants infected with HBV will become carriers. Among 
these, 25 per cent will, in the long term, develop serious liver disease. 
Approximately 14 to 16 million people are infected with HBV each year 
in the region. It is estimated that approximately 2 lakh deaths associated 
 
 
 
with acute HBV infection and related disease occur in the Region 
annually. 
Based on the different HBsAg carrier rates, countries of the Region 
can be divided into three epidemiological patterns. The Type 1 occurs in 
Nepal and Sri Lanka and is characterized by a low HBsAg carrier rate of 
0.9 to 1.0 per cent. The second pattern (Type 2) can be found in Bhutan, 
India, Indonesia and Maldives where carrier rate is high in the general 
population (5 to 7 per cent). In India alone there are an estimated 43 to 45 
million HBsAg carriers and, among them 10 to 12 million also have 
HBeAg. Type 3 is observed in Bangladesh, DPR Korea, Myanmar and 
Thailand, where the carrier rate is very high and ranges from 9 per cent to 
12 per cent.  
In India, the carrier rate of HBsAg in hospital staff has been found 
to be higher (10.87 per cent) than in voluntary blood donors (6 per cent) 
and in the general population (5 per cent).  
 
 
 
REVIEW OF LITERATURE  
 
 Hepatitis B Virus is a DNA virus with remarkably compact 
genomic structure, despite its small, circular, 3200 – bp size, HBV DNA 
 
 
 
codes for four sets of viral products with a complex, multiparticle 
structure. HBV achieves its genomic economy by relying on an efficient 
strategy of encoding portents from four overlapping genes. S,C, P and X.  
HBV is recognized as one of our family of animal viruses, hepadna 
virueses and is classified as hepanda virus type – 1.  
HBV has three distinctive three morphological forms. The most 
numerous are the 22nm particles, which appear as spherical or long 
filamentous forms; these are antigenically indistinguishable from the 
outer surface are envelope protein of HBV and are thought to represent 
excess viral envelope protein.  
The envelope protein expressed on the outer surface of the virion 
and on the smaller spherical and tubular structures is referred to as 
hepatitis B surface antigen (HBsAg). The envelope protein HBsAg is the 
product of S gene of HBV.  
 The intact 42-nm virion contains 27 –nm nucleocapsid core 
particle. Nucleocapsid proteins are coded for by the C gene, The antigen 
expressed on the surface of the nucleocapsid core is referred to as 
hepatitis B core antigen (HBcAg) and its corresponding antibody is anti – 
HBc.  
 
 
 
 A third HBV antigen is hepatitis B e antigen (HBeAg), a soluble, 
nonparticulate, nucleocapsid protein that is immunologically distinct from 
intact HBcAg but is a product of the same C gene. The C gene has two 
initiation codons, a precore and a core region. If translation is initiated at 
the precore region, the protein product is HBeAg, which has single 
peptide that binds it to the smooth endoplasmic reticulum and leads to its 
secretion into the circulation. If translation begins with the core region, 
HBcAg is the protein product; it has not single peptide, it is not secreted, 
but it assembles into nucleocapsid particles, which bind to incorporate 
RNA and which, ultimately contain HBV DNA.  
 HBcAg particles remain in the hepatocyte, where they are readily 
detectably by immunohistochemical staining, and are exported after 
encapsidation by an envelope of HBsAg. Therefore, naked core particle 
do not circulate in the serum. The secreted nucleocapsid protein. HBeAg, 
provides a convenient, readily detectable, qualitative marker of HBV 
replication and relative infectivity.  
            HBsAg – positive serum containing HBeAg is more likely to be 
highly infectious and to be associated with the presence of hepatitis B 
virions than HBeAg – negative or anti HBe – Positive serum.  
 
 
 
 Early during the course of acute hepatitis B, HBeAg appears 
transiently, its disappearance may be a harbinger of clinical improvement 
and resolution of infection. Persistence of HBeAg in serum beyond the 
first 3 months of acute infection may be predictive of the development of 
chronic infection and the presence of HBeAg during chronic hepatitis B 
is associated with ongoing viral replication, infectivity, and inflammatory 
liver injury. 
  The third of the HBV genes is the largest, the P gene which codes 
for the DNA polymerase. This enzyme has both DNA dependent DNA 
polymerase and RNA dependent reverse transcriptase activities. The 
fourth  gene, X, codes for a small, non-particulate protein, hepatitis B x 
antigen (HBxAg).  
 
 
 
 
 
TRANSMISSION 
HBV is parenterally transmitted via blood or blood products or by 
sexual or perinatal exposure, the same routes as for HIV; hence, there are 
many similarities in the epidemiology of these two viruses. Viral 
particles, which are capable of transmitting infection to chimpanzees, are 
detectable in body secretions, including semen and saliva. Thus, contact 
with mucous membranes and their secretions is likely to be a mode of 
transmission of HBV. 
 
 
 
 
PERINATAL AND EARLY CHILDHOOD TRANSMISSION 
HBV is most prevalent in people born in regions of high HBV 
endemism and their descendants. High levels of virus in serum (signified 
by HBV DNA and HBeAg positivity) have been associated with an 
increased risk of transmission by needle stick exposure and by vertical 
routes.  Infants born to HBeAg-positive mothers who have high levels of 
viral replication (HBV DNA level >80 pg/mL) have a 70% to 90% risk of 
perinatal acquisition in the absence of interventions. In contrast, the risk 
of mother-to-infant transmission from HBeAg-negative mothers is 
substantially lower (10%–40%). Infection occurs through occult 
inoculation of the infant at the time of birth or shortly thereafter. IgM 
anti-HBc is not detectable in cord blood, so that intrauterine infection is 
unlikely to have occurred. Even with active and passive immunization, 
5% to 10% of babies may acquire HBV infection at birth. 
Children of HBsAg-positive mothers who are not infected at birth 
remain at high risk of early childhood infection; 60% become infected by 
the age of 5 years.The mechanism of this later infection, which is neither 
perinatal nor sexual, is unknown. Although HBsAg can be detected in 
breast milk, breast-feeding is not believed to be an important mode of 
transmission. Children living in areas of high endemism may acquire 
infection outside the family. 
 
 
 
SEXUAL TRANSMISSION 
Sexual activity is probably the single most important mode of HBV 
transmission in areas of the world such as North America, where the 
prevalence of infection is low. From 1980 to 1985, men who had sex with 
men were at particularly high risk of HBV infection and accounted for 
20% of all reported cases of HBV infection. Factors associated with a 
high risk of viral acquisition in this patient population included multiple 
sexual partners, anal-receptive intercourse, and duration of sexual 
activity.  The risk has fallen markedly in recent reports (to 8% of all 
cases), probably because of modifications of sexual behavior in response 
to the acquired immunodeficiency syndrome (AIDS) epidemic.  
Unfortunately, advanced liver disease from HBV infection is emerging as 
an important medical problem for patients infected with HIV (see later). 
Heterosexual sex now accounts for the majority of cases of HBV 
infection (26%) with an identifiable risk factor in the United States.  In 
heterosexuals, factors associated with an increased risk of HBV infection 
include duration of sexual activity, number of sexual partners, a history of 
sexually transmitted diseases, and positive serologic results for syphilis. 
Sexual partners of injection drug users, prostitutes, and clients of 
prostitutes are at particularly high risk of HBV infection. 
 
 
 
Sexual partners of persons infected with HBV are at risk for 
infection, even in the absence of high-risk behavior. Studies of sexual and 
household contacts of HBV carriers have shown that 0% to 3% of the 
spouses or sexual partners and 4% to 9% of the children are HBsAg 
positive. Moreover, there is a high prevalence of markers of prior HBV 
infection in these two groups (29%–59% of spouses or sexual contacts 
and 9%–12% of children).  Because many patients with chronic HBV 
infection are unaware of their infection and are "silent carriers," sexual 
transmission is likely to be an important mode of transmission 
worldwide. As with perinatal transmission, sexual transmission is 
facilitated by active viral replication in the infected person. The risk of 
heterosexual transmission is greater when the infected person is female 
than when the infected person is male.  The use of condoms appears to 
reduce the risk of sexual transmission. Sexual transmission may also 
account for some of the approximately 30% to 40% of all cases in the 
United States in which no known risk factor can be identified. 
 
 
 
INJECTION DRUG USE 
In the United States and Western Europe, injection drug use remains a 
very important mode of HBV transmission (23% of all cases). The risk of HBV 
infection increases with duration of drug use, so that serologic markers of 
ongoing or prior HBV infection are almost universal after 5 years of drug use. 
OTHER MODES OF TRANSMISSION 
Other risk factors for HBV infection include working in a health-
care setting (3% of cases in the United States), transfusions and dialysis 
(1% each), acupuncture, tattooing, travel abroad, and residence in an 
institution.  Although the risk of transfusion-associated HBV infection 
has been greatly reduced with the screening of blood (with tests to detect 
HBsAg and anti-HBc) as well as exclusion of donors who engage in high-
risk activities, it is estimated that 1 in 50,000 transfused units transmits 
HBV infection. Acupuncture has been associated with outbreaks of HBV 
infection. In World War II, contaminated plasma-stabilized yellow-fever 
vaccine was associated with one of the largest epidemics of HBV 
infection, in which icteric hepatitis developed in 50,000 U.S. army 
personnel. Nosocomial spread of HBV infection in hospitals, particularly 
in dialysis units as well as in dental units, has been well described, even 
when current infection control practices are followed. HBV infection has 
 
 
 
been linked to multiple-use heparin vials. As with other modes of 
transmission, high viral titers in serum have been related to an increased 
risk of transmission. HBV remains infectious in the environment for 7 
days or longer, so that contaminated surfaces may account for 
transmission in the absence of a known exposure. 
SEROLOGICAL AND VIROLOGIC MARKERS  
 After a person is infected with HBV, the first virologic marker 
detectable in serum within 1-12 weeks, usually between 8-12 weeks, is 
HBsAg. Circulation HBsAg precedes elevation of serum 
aimnotransferease activity and clinical symptoms by 2-6 weeks and 
remains detectable during the symptomatic phase of  acute hepatitis B 
and beyond. HBsAg becomes undectable 1-2 months. After HBsAg 
disappears, antibody to HBsAg becomes detectable in serum and remains 
detectable indefinitely thereafter. Because HBcAg in instracellular and, 
when in the serum, sequested within an HBcAg coat, naked core particles 
do not circulate in serum and therefore, HBcAg is not detectable routinely 
in the serum of patients with HBV infection. By contrast, anti – HBc is 
readily demonstrable in serum, beginning within the first 1-2 weeks after 
the appearance of HBsAg and preceding detectable levels of anti – HBs 
by weeks to months.  
 
 
 
 
 HBV infection can be distinguished by determination of the 
immunoglobulin class of anti – HBc. Anti HBc of the IgM class (IgM anti 
– HBc) predominates during the first 6 months after acute infection, 
whereas IgG anti – HBc is the predominant class of anti – HBc beyond 6 
months. Therefore, patients with current or recent acute hepatitis B, 
including those in the anti – HBc windows, have IgM anti – HBc in their 
serum. In patients who have recovered from hepatitis B in the remote past 
as well as those with chronic HBV infection, anti – HBc is predominantly 
of the IgG class.  
 
 
 
 
 The other readily detectable serologic marker of HBV infection, 
HBcAg, appears concurrently with or shortly after HBsAg. Its appearing 
coincides temporally with high levels virus replication and reflects the 
presence of circulating intact virions and detectable HBV DNA.  
 In chronic HBV infection, HBsAg remains detectable beyond 6 
months, anti- HBc is primarily of the IgG class, and anti – HBs is either 
undetectable or detectable at low levels. During early chronic HBV 
infection, HBV DNA can be detected both in serum and in hepatocyte  
nuclei, where it is present in free or episomal form. This replicative stage 
of HBV infection is the time of maxminal infectivity and liver injury; 
HBeAg is a qualitative marker and HBV DNA a quantitative marker of 
this replication phase during which all three forms of HBV circulate, 
including intact virions. Over time the replicative of chronic HBV 
infection gives way to a relatively non-replectative phase.  
 This occurs at a rate of ~ 10% per year and is accompanied by 
seroconversion from HBeAg – positive to anti – HBe positive. In most 
cases this seroconversion coincides with a transient acute hepatitis like 
elevation in aminotransferase activity, believed to reflect cell immune 
clearance of virus infected hepatocytes. In the non-replicative phase of 
chronic infection when HBV DNA is demonstrable in hepatocyte nuclear, 
 
 
 
it tends to be integrated into the host genome. HBV replication can be 
detected a level of ~ less than 103 virions with highly sensitive 
amplification probes such as the polymerase chain reaction (PCR) ; below 
this replection threshold liver injury and infectivity of HBV are limited to 
negligible. Because of IgM anti-HBc, can reappear during acute 
exacerbations of chronic hepatitis B, relaying on IgM anti – HBc versus 
IgG anti – HBc to distinguish between acute and chronic hepatitis B 
infection, respectively, may not always be reliable, in such cases, patient 
history is invaluable in helping to distinguish de novo acute hepatitis B 
infection from acute exacerbation of chronic hepatitis B infection.  
 
 
 
 
Groups in which acute and chronic type B 
hepatitis should be suspected 
 
Immigrants from Mediterranean countries, Africa or the Far East 
Drug abusers 
Homosexual men 
Neonates of HBsAg-positive mothers 
Hospital staff 
Patients with 
renal failure 
reticuloses 
cancer 
organ transplants 
Staff and patients of hospitals for the mentally retarded 
 Post-transfusion 
 
 
 
 
HBV CARRIERS 
Approximately 10% of patients contracting hepatitis B as adults 
and 98% of those infected as neonates will not clear HBsAg from the 
serum within 6 months. Such patients become carriers and this is likely to 
persist. Reversion to a negative HBsAg is rare, but may develop in old 
age. Males are six times more likely to become carriers than females. The 
dilemma of a person, such as a hospital worker, carrying the antigen and 
coming from an area where it is prevalent is a very difficult one. Hospital 
staff who develop HBsAg-positive hepatitis and clear the antigen from 
the blood are immune to type B hepatitis. If they become carriers, the 
position is difficult.‘Healthy’ carriers may show changes on liver biopsy 
ranging from non-specific minimal abnormalities through to chronic 
hepatitis and cirrhosis. The extent of the changes is not reflected by 
serum biochemical tests and may only be revealed by liver biopsy. The 
carrier presenting by chance is likely to have minor hepatic changes 
compared to the patient presenting to a gastroenterology department 
where more serious liver disease is probable. In a survey of patients 
found to be HBsAg positive at blood donation, 95% had near normal liver 
biopsy. 
 
 
 
 
PATHOGENESIS 
Immune Pathogenesis 
Clinical observations suggest that the immune response of the host 
is more important than viral factors in the pathogenesis of liver injury 
caused by HBV. Chronic HBV carriers who have normal liver enzyme 
levels and normal or near-normal liver histologic studies, despite high 
levels of viral replication, have been well described; significant liver 
injury would be predicted if the virus were directly cytopathic. Similarly, 
HBV can be grown in hepatocyte culture with no adverse effect on cell 
viability. Other clinical observations point to the importance of an intact 
immune response in mediating liver injury. Infants with immature 
immune systems who acquire HBV infection at birth have a high rate of 
chronic infection and replication yet typically have only mild liver injury. 
Conversely, HBV-induced fulminant hepatic failure is associated with a 
vigorous immune response, low serum levels of virus, and massive 
hepatocellular necrosis. 
There has been extensive investigation in both humans and 
experimental animals of specific immune responses associated with HBV 
clearance (or conversely persistence) and liver injury. In acute infection, a 
specific immune response to multiple viral antigens can be demonstrated 
 
 
 
in both major histocompatibility complex (MHC) class II–restricted and 
MHC class I–restricted T cells (CD4+ and CD8+, respectively, the latter 
making up the majority of CTLs).  T helper cell responses to core and 
polymerase proteins are particularly strong, with lesser responses to the 
envelope proteins. In patients with chronic HBV infection who fail to 
clear the virus, the number of both CD4+ and CD8+ T cells is markedly 
reduced. In contrast, the humoral immune response is preserved in both 
acute and chronic HBV infection, although anti-HBs usually cannot be 
detected in the latter because of antigen excess. 
There are few animals models with which to investigate the pathogenesis 
of liver injury and the mechanisms of viral clearance in hepadnaviral 
infections. Transgenic mouse models have been used to examine specific 
mechanisms by which CTLs clear virus and cause hepatocyte necrosis. 
These mice are naturally tolerant to the "transgene," that is, to different 
components of the HBV genome, yet their immune response can be 
reconstituted with infusion of CTLs from non-transgenic mice immunized 
with different HBV proteins.  Acute liver injury associated with CTL 
infiltration of the liver develops in a dose-dependent manner in recipients 
of these cells. 
 
 
 
It has been widely accepted that CTLs are responsible for 
destruction of virally infected hepatocytes and for viral clearance. 
However, the number of CTLs involved is generally much fewer than the 
number (1011) of virally infected hepatocytes. Thus, secondary non–
antigen-specific immune responses, such as those mediated by 
inflammatory cytokines, may be more important for viral clearance than 
the CTL-mediated mechanism. Recent data point to the importance of 
tumor necrosis factor-α (TNF-α) and gamma-interferon as prime 
mediators of this non–antigen-specific clearance of HBV. These 
cytokines activate two independent pathways that result in elimination of 
HBV nucleocapsid cores and destabilization of viral RNA. These 
cytokines may also be important in the clearance of HBV in chronically 
infected patients who become superinfected with other hepatotropic 
viruses. 
VIRAL PATHOGENESIS 
Variant Viruses 
Although there are a variety of serotypes and genotypes of HBV, 
there is remarkably little genomic variability in this virus. Nevertheless, 
mutant forms of HBV with mutations in the precore, surface, and X 
genes, as well as the core promoter region, have been implicated in a 
 
 
 
number of clinical syndromes. Polymerase variants that are selected by 
exposure to nucleoside analogues have recently been described. These 
polymerase variants may be less replication-competent and even less 
pathogenic than the wild-type virus  and are discussed in greater detail in 
the section on treatment. Several recent review articles describe the 
clinical significance of HBV variants and suggest changes in the 
nomenclature of the mutations associated with these variants. 
PRECORE/CORE VARIANTS 
Although the majority of Northern European and American 
patients with chronic HBV infection and active viral replication are 
HBeAg positive, many Southern European and Asian patients have 
severe liver disease and active viremia in the absence of HBeAg. 
Sequence analysis of the precore region of HBV isolated from such 
patients has revealed a point mutation (G to A) at nucleotide position 
1896 that results in the production of a translational stop codon predicted 
to stop translation of HBeAg. In contrast, production of core peptide 
continues because translation of this protein is initiated at a start codon 
downstream from the site of mutation. Such variant viruses have also 
been described in association with fulminant liver failure and severe 
chronic liver disease. Whether these precore mutants are etiologically 
 
 
 
important in these syndromes or whether they merely emerge in 
association with severe disease remains controversial. Moreover, if the 
precore mutants are etiologically associated with these syndromes, the 
mechanism by which the virus causes these syndromes is unknown. 
Several hypotheses have been put forward, including 1) a heightened 
immune response against core peptide expressed on hepatocytes in the 
absence of "immune deflection" by HBeAg in serum (see previous 
section); 2) direct cytopathicity of the truncated HBeAg fragment that is 
synthesized as a result of early termination of translation of precore/core 
mRNA; 3) enhanced replication of mutant virus over wild-type virus 
because of increased stability of the hairpin stem-loop of the HBV 
genome, which encodes the encapsidation signal for viral packaging. In 
the United States, only a small proportion of all cases of HBsAg-positive 
fulminant liver failure is associated with variant viruses. 
Mutations in the core promoter region have also been proposed to 
result in failure of HBeAg production. These mutant viruses, which 
involve nucleotide substitutions at positions 1762 and 1764, may decrease 
transcription of mRNA that encodes HBeAg. Core promoter variants 
have been described in association with 10% of cases of fulminant HBV 
 
 
 
infection, 10% of cases of acute self-limited hepatitis, and 27% of cases 
of progressive chronic hepatitis. 
Although there has been a great deal of interest generated by the 
discovery of HBV variants, the clinical significance of these mutant 
viruses, particularly those described in association with severe liver 
disease, remains controversial. The presence of precore variants is also 
associated with the distribution of HBV genotypes. In patients with 
genotype A HBV infection (the predominant genotype in North America 
and Europe), nucleotide (nt) 1858 is a C. In this genotype, both a 
mutation at nt 1896 (G to A) and nt 1858 (C to T) would be required to 
stabilize the stem-loop structure of the HBV genome. Without a 
compensatory mutation at nt 1858 in genotype A, impaired base pairing 
results when C-1858 tries to pair with A-1896, thereby destabilizing the 
stem-loop structure of the packaging signal and leading to a decrease in 
encapsidation and in viral replication. Thus, precore stop codon mutations 
may be less frequent in genotype A because of the need for two 
mutational events. By contrast, in countries where precore mutants are 
common, genotypes B, C, D, and E are predominant. In these patients 
only one mutation at nt 1896 is required to yield a precore mutant with 
stable stem-loop pairing of the genome. 
 
 
 
SURFACE GENE MUTANTS 
Immune escape from neutralizing antibodies occurs in a region of 
HBV known as the "a" determinant. This hydrophilic region from amino 
acids 124 to 147 is highly conserved between subtypes of HBV and is 
believed to be important in eliciting protection against infection. The 
glycine at amino acid 145 in particular is highly conserved among HBV 
subtypes, and a G-to-A nucleotide substitution produces amino acid 
changes at this position that result in major antigenic changes in the virus. 
Escape mutants have been described in babies who have received 
immunoprophylaxis with polyclonal hepatitis B immune globulin 
(HBIG). Despite protective levels of antibody, these babies became 
HBsAg positive and developed chronic liver disease. Virus from such a 
baby demonstrated a G-to-A substitution at amino acid 145 compared 
with the viral isolate from the mother, and the mutant virus bound HBIG 
with lower affinity than did the "wild-type" virus. Emergence of surface 
gene mutants in liver transplant recipients receiving monoclonal HBIG 
therapy has also been described.  As with the "vaccine-escape" mutants, 
these viruses fail to bind anti-HBs with high affinity. Because of the very 
compact nature of the genomic organization of HBV, changes in the "a" 
determinant have the potential to alter the function of the HBV 
 
 
 
polymerase, an enzyme essential for viral replication. The G-to-A 
mutation in the "a" determinant may give rise to a stop codon (TAG) (if 
the nucleotide before this mutation is a T), which would have profound 
effects on viral replication and the pathogenesis of disease. 
LOW-LEVEL HBV INFECTION 
The existence of HBsAg-negative HBV infection has long been 
debated.  Low-level HBV infection is implicated or has been documented 
in the following clinical situations: a) HBV infection has been transmitted 
by transfusion of a unit of blood from an HBsAg-negative, anti-HBc-
positive blood donor; b) HBV DNA has been detected in serum and liver 
from persons lacking all serologic markers of HBV infection. Serum from 
serologically negative, HBV DNA–positive persons can transmit HBV 
infection to chimpanzees; c) occult HBV infection has been reported in 
association with apparent fulminant hepatic failure in patients who lack 
all serologic markers of HBV or HAV infection (so-called non-A, non-B 
fulminant hepatic failure), although these results are controversial ; d) 
low-level HBV infection has been detected in patients with a variety of 
causes of chronic liver disease and in association with primary 
hepatocellular carcinoma. Even in regions of low endemism for HBV, 
such as France, 11 of 22 HBsAg-negative patients with hepatocellular 
 
 
 
carcinoma had detectable HBV DNA in serum.  Molecular studies have 
demonstrated selective accumulation of RNA encoded by the X gene in 
association with HBsAg-negative hepatocellular carcinoma) HBsAg-
negative patients may become HBsAg positive and develop overt 
hepatitis with cancer chemotherapy or immunosuppression following 
kidney transplantation. Presumably low-level HBV infection is the source 
of viral reactivation that is unmasked by immunosuppression. 
Whether viral or host immune factors enable persistence of HBV 
infection in the absence of HBsAg is unclear. Two hypotheses have been 
proposed to explain the atypical serologic profiles in these patients. The 
first hypothesis suggests that mutations in the viral genome result in 
impaired antigen production by the virus. Numerous mutations in HBV, 
particularly in the region of the gene for HBsAg, have been reported and 
may facilitate viral persistence. The second hypothesis suggests that the 
host immune system keeps the virus in a quiescent or latent state until 
immunosuppressive therapy results in viral reactivation. 
 
 
 
CLINICAL MANIFESTATIONS 
Acute Infection 
The incubation period from acute exposure to clinical symptoms 
ranges from 60 to 180 days . Clinical presentation varies from 
asymptomatic infection to cholestatic hepatitis with jaundice, and rarely 
liver failure. In acute infection, HBsAg and markers of active viral 
replication (HBeAg and HBV DNA by hybridization assays) become 
detectable approximately 6 weeks after inoculation, before the onset of 
clinical symptoms or biochemical abnormalities. These tests remain 
positive throughout the prodromal phase and during the early clinical 
phase of the illness. Biochemical abnormalities usually coincide with the 
prodromal phase of the acute illness and may persist for several months. 
With the onset of symptoms, IgM anti-HBc becomes detectable. IgM 
anti-HBc may persist for many months, and IgG anti-HBc may persist for 
many years, if not a lifetime. Anti-HBs is the last serologic test to become 
positive and is a marker of resolving infection (as HBsAg titers fall). 
Much has been made of the serologic window period when neither 
HBsAg nor anti-HBs is detectable and IgM anti-HBc is the only marker 
of acute infection. However, with currently available serologic assays, 
this window period is rare. 
 
 
 
The biochemical diagnosis of acute hepatitis depends largely on 
measurements of serum bilirubin and aminotransferase levels. The serum 
alanine aminotransferase (ALT) level is typically higher than the serum 
aspartate aminotransferase (AST) level, and levels of both 
aminotransferases are usually 500 U/L or greater. Bilirubin elevations are 
usually modest (5–10 mg/dL), although they may be higher in the setting 
of hemolysis or renal failure. 
The most profound complication of acute HBV infection is 
fulminant hepatic failure, defined as the onset of hepatic encephalopathy 
within 8 weeks of the onset of symptoms. Although this complication is 
infrequent (occurring in less than 1% of cases), the prognosis is poor once 
encephalopathy has developed. When patients present with acute 
hepatitis, it is essential to obtain tests of hepatic synthetic function 
(prothrombin time, serum albumin). Evidence of a prolonged 
prothrombin time (International Normalized Ratio [INR] of 1.5 or greater 
or prothrombin time of 17 seconds or longer) should raise concern 
regarding the potential development of fulminant hepatic failure. If 
clinical symptoms of hepatic failure develop, patients should be referred 
for consideration of liver transplantation. 
 
 
 
Current serologic assays for the diagnosis of acute and chronic 
HBV infection (HBsAg and HBeAg) are both sensitive and specific. 
HBsAg, HBeAg, anti-HBc, and anti-HBe are detected by standardized 
enzyme-linked immunoassays (EIAs). The detection of HBsAg indicates 
active HBV infection, and the detection of HBeAg indicates active viral 
replication and increased infectivity. Characteristic serologic changes 
develop in relation to clinical symptoms and biochemical abnormalities in 
acute resolving infection and in acute followed by chronic infection. 
CHRONIC INFECTION 
In acute HBV infection that progresses to chronicity, early events 
are similar to those in acute HBV infection that resolves. However, with 
chronic infection, HBsAg, HBeAg, and HBV DNA remain positive for 6 
months or longer. After the acute phase of infection, serum ALT levels 
fall but often remain persistently abnormal (from 50 to 200 U/L). IgM 
anti-HBc titers typically fall to undetectable levels after 6 months but 
may become detectable again during reactivation of infection. IgG anti-
HBc persists indefinitely. HBV DNA is detectable by hybridization 
assays during the acute and chronic phases of disease. With time, there 
may be a spontaneous loss of HBV DNA and HBeAg, frequently in 
association with a flare of serum ALT levels and seroconversion to anti-
 
 
 
HBe positivity. Spontaneous loss of HBsAg is rare. Anti-HBs may be 
detected simultaneously with HBsAg in serum in fewer than 10% of 
cases. In some cases of chronic infection, active viral replication (HBV 
DNA positivity) occurs in the absence of HBeAg (see previous section). 
The presence of anti-HBs is associated with immunity to HBV 
infection. Isolated anti-HBs is more likely to be acquired by vaccination 
than by natural infection, in which both anti-HBs and IgG anti-HBc are 
typically present. Much confusion surrounds the interpretation of isolated 
anti-HBc positivity. The significance of this finding depends on the 
patient population in which it is observed. Fifty percent of patients with 
chronic HCV infection are anti-HBc positive, and in these patients, who 
have had frequent parenteral exposure, the anti-HBc positivity likely 
represents resolved HBV infection or low-level HBV infection of minor 
clinical significance. In Alaskan natives, a group with a high prevalence 
of HBV infection, vaccination against HBV has been used to determine 
whether isolated anti-HBc signifies prior exposure; those with a primary 
immune anti-HBs response were deemed to have a false-positive anti-
HBc, whereas those with an anamnestic response were deemed to have a 
true-positive anti-HBc, indicative of prior or ongoing low-level HBV 
infection. In blood donors who have been pre-screened for parenteral risk 
 
 
 
factors, an isolated anti-HBc, particularly if it is of low optical density on 
EIA, likely represents a false-positive result. Because there is no readily 
available "gold standard" for the diagnosis of resolved or ongoing low-
level HBV infection, the interpretation of an isolated positive anti-HBc 
remains problematic 
Extrahepatic Manifestations 
Extrahepatic findings are common in patients with acute HBV 
infection. Arthralgias and rashes occur in 25% of cases. A severe serum 
sickness–like syndrome with immune complex deposition occurs more 
rarely and can result in angioneurotic edema. Polyarteritis nodosa with a 
systemic vasculitis can occur with either acute or chronic HBV infection. 
This syndrome typically presents with abdominal pain resulting from 
arteritis of the medium-sized arteries with ischemia to the intestine or 
gallbladder. Other manifestations of HBV-associated vasculitis include 
neuropathy (mononeuritis), renal disease, cutaneous vasculitis, arthritis, 
and Raynaud's phenomenon. Chronic, and to a lesser extent acute, HBV 
infection has also been associated with membranoproliferative 
glomerulonephritis resulting from deposition of immune complexes in the 
basement membrane of the glomerulus. The syndrome of type II mixed 
essential cryoglobulinemia was previously believed to be caused largely 
 
 
 
by HBV infection but has been shown to be associated more frequently 
with chronic HCV infection (see later section). Neurologic manifestations 
of HBV infection include Guillain-Barré syndrome and a polyneuropathy 
(usually related to polyarteritis). HBV infection is rarely associated with 
pericarditis and pancreatitis. 
COMPLICATIONS 
Patients with chronic HBV infection are at risk of developing long-
term complications of portal hypertension and hepatic decompensation, 
such as variceal bleeding, ascites, and hepatorenal syndrome, as well as 
HCC, which may ultimately result in death. When complications occur, 
referral for liver transplantation should be considered. Evolving antiviral 
therapies, discussed later, have greatly improved the outcome of patients 
with HBV infection after liver transplantation. 
Patients with chronic liver disease, particularly those with 
established cirrhosis, are at increased risk of developing HCC. The risk of 
developing HCC is increased 10- to 390-fold in patients with chronic 
HBV infection compared with those who are HBsAg negative and is 
greater in those who acquired HBV infection perinatally than in those 
who acquired the infection as adults. In regions where HBV is endemic, 
HCC is the leading cause of cancer-related deaths. 
 
 
 
Despite this strong epidemiologic link between HBV infection and 
HCC, and despite active research in this area for more than a decade, the 
mechanism by which HBV causes malignant transformation has not been 
elucidated. Comparison of HBV DNA sequences with those of known 
oncogenes has failed to identify a specific viral oncogene. Activation of 
an adjacent host cellular oncogene may occur during the process of HBV 
genome integration, but the viral genome does not integrate into the host 
genome in any consistent pattern. Cirrhosis of the liver is present in more 
than 90% of patients with HCC related to HBV, suggesting that the 
presence of cirrhosis is a risk factor for HCC development. Chronic 
inflammation associated with active viral replication, together with 
ongoing cellular proliferation and regeneration associated with cirrhosis, 
is likely a predisposing factor that leads to cellular transformation and 
frank malignancy. 
LABORTORY FEATURES  
             The serum aminotransferases aspartate aminotransferase (AST) 
and ALT show a variable increase during the prodromal phase of acute 
viral hepatitis precedes the rise in bilirubin level.  
 
 
 
 
   The acute level of these enzymes, however, does not correlate 
well with the degree of liver cell damage. Peak levels vary from 400 – 
4000 IU or more, these levels are usually reached at the time the patient is 
clinically icteric and diminish progressively during the recovery phase of 
acute hepatitis.  The diagnosis of anicteric hepatitis is based on clinical 
features and on aminotransferase elevations.  
 The serum bilirubin may contribute to the rise despite falling serum 
aminotranferase levels. In most instances, the total bilirubin is equally 
divided between the conjugated and unconjugated fractions. Bilirubin 
level > 340 umol/L (20mg/dL) extending and persisting late into the 
course of viral hepatitis are more likely to be associated with severe 
disease.  
 Neutropenia and lymphopenia are transient and are followed by 
relative lymphocytosis. Atypical lymphocytes are common during the 
acute phase. Measurement of prothrombin time is important with acute 
viral hepatitis for a prolonged value may reflect a severe hepatic synthetic 
defect, signify extensive hepatocellular necrosis, and indicate a worse 
prognosis.  
 
 
 
 Serum IgG and IgM levels are elevated in about one – third of 
patients during the acute phase of viral hepatitis but the serum IgM level 
is elevated more characteristically during acute hepatitis.  
 Diagnosis of HBV infection can usually be made by detection of 
HBsAg  in the serum. Infrequently levels of HBsAg are too low to be 
detected during acute HBV infection even with contemporary, high 
sensitive immunoassays. In such cases the diagnosis can be established 
by the present of IgM anti- HBc.  
 The titer of HBsAg bears little relation to the severity of clinical 
disease. Indeed, an inverse correlation exists between serum 
concentration of HBsAg and the degree of liver cell damage. For example 
titers are highest in immunosupperssed patients, lower in patient with 
chronic liver disease and very low in patients with acute fulminant 
hepatitis. These observation suggest that, in hepatitis B, the degree of 
liver damage and the clinical course are related to variations in the 
patients immune response to HBV rather than to the amount of 
circulating HBsAg. Immunocompetent persons, however, there is a 
correlation between markers of HBV replication and liver injury.  
 
 
 
 
 Another serologic marker that may be value in patients with 
hepatitis B is HBeAg. Its principal clinical usefulness is as an indicator of 
relative infectivity. Because HBeAg is invariably present during early 
acute hepatitis B, HBeAg testing is indicated primarily during follow up 
to chronic infection.  
 Anti – HBs is rarely detectable in the presence of HBsAg in 
patients with acute hepatitis B, but 10-20% of person with chronic HBV 
virus infection may harbor low – level anti – HBs. This antibody is 
directed not against the common group determinant, but against the 
heterotypic subtype determinant, in most cases this serological pattern 
cannot be attributed to infection with two different HBV subtypes, and 
the presence of this antibody is not harbinger of imminent HBsAg 
clearance.  
 After immunization with hepatitis B vaccine, which consists of 
HBsAg alone, anti – HBs is the only serologic marker to appear.  
Like HBeAg, serum HBV DNA is an indicator of HBV replication, 
but tests for HBV DNA are more sensitive and quantitative.  
 
 
 
 
Currently, testing of HBV DNA has shifted from insensitive 
hybridization assays to amplification assays, example PCR based assay, 
which can detect as few as 10-100 virions/ml ; among the commercially 
available PCR assays, the most useful are those with high sensitive (5-10 
IU/mL) the largest dynamic range (10o-109 IU/ml).  
                   
           
           
 
 
                                
 
 
 
AIMS AND OBJECTIVES 
 
 
 
 
This study was undertaken to establish the relationship between 
biochemical, serological, histological and viral replication indices in an 
individual with incidentally detected asymptomatic HBsAg positive. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIAL AND METHODS 
 
This study was undertaken in 112 asymptomatic subjects 
incidentally detected to be HBsAg positive with ALT levels less than five  
the upper limit of normal, attending the  Department of Medical 
Gastroenterology, COIMBATORE MEDICAL COLLEGE HOSPITAL, 
COIMBATORE between September 2007 to September 2009. Their 
 
 
 
clinical, biochemical, virological and histological assessment was done. 
39 patients were lost on follow up. 
 
INCLUSION CRITERIA : 
1. HBsAg positivity on 2 occasions.  
2. IgM Anti-HBc negative.  
3. ALT (<5 times normal). 
 
EXCLUSION CRITERIA: 
1. History of jaundice <1 year. 
2. Presence of Ascitis. 
3.  GI Bleeding . 
4. Hepatic Encephalopathy. 
5. Pregnant women. 
6. Those with immunodeficiency (renal/bone marrow 
transplant recipients or those on cancer chemotherapy / 
Hemodialysis. 
7. Co infection with HIV or Hepatitis C. 
8. Alcohol consumption >20 gm/day for >5 year.  
 
 
 
9. The study was approved by the ethics committee of 
Coimbatore Medical College Hospital, Coimbatore. 
 
 
 
 
                                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
METHODOLOGY 
All the subjects were interviewed on the basis of a pre designed 
questionnaire regarding occupation, exposure to unsterilised needle and 
syringes. Blood transfusion, post history of Jaundice (etiology and 
outcome) any family member suffering from Hepatitis B/C/E, history of 
ingestion of any hepatotoxic drugs, alcohol injection (amount, since how 
many year), any surgical procedure, high risk behaviors as intravenous 
drug abuse, sexual promiscuity, family history of chronic liver disease, 
tattooing shaving razor, blade etc. none of the patients had a history of  
Hemodialysis or organ transplantation. Detailed general examination was 
carried out to look signs of chronic liver disease. 
All the subjects serum were tested for serum Bilirubin, ALT,AST, 
HBeAg, IgM anti-HBc, anti HCV, HIV, and HBV DNA (quantitative by 
PCR)  
The subjects were divided into following groups :Group 
A(6):HBeAg positive,HBV DNA >105, ALT >40 (ie 40IU/ml).Group 
B(4):HBeAg positive, HBV DNA >105, ALT < 40.Group C(12):HBeAg 
negative, HBV DNA > 10000 copies/ml, ALT > 40.Group D(16):HBeAg 
 
 
 
negative, HBV DNA >  10000 copies/ml, ALT<40.Group E(35):HBeAg 
negative, HBV DNA <10000 copies/m, ALT <40  
Liver biopsy for HAI scoring was done in group A, B, C and D 
individuals, after taking written informed consent. 
Biochemical parameter (ALT, AST, Serum Bilirubin )were 
measured using  an auto analyser. Prothrombin time was measured using 
Quick method at the time of Liver biopsy. 
The sera of the subjects were tested for HBsAg, IgM HBcAg, 
HBeAg and Anti-HBe (VIDAS automated module using enzyme linked 
Fluorescent immunoassay [ELFA], biomerieux Sa, France) anti HCV (3rd 
generation ELISA Kit, ELISCANTM HCV), HIV I and II and p24 [MINI 
VIDAS (ELFA)] and HIV DUO ULTRA (HIV5). 
Test for HBV DNA was done in sera of all subjects from using 
“Real Time Polymerase Chain Reaction”. It involves the specific 
amplification of a 134bp region of the HBV genome. This analysis is 
done on Rotor Gene 3000 by using the highly sensitive & specific 
TAQMAN assay method. The TAQMAN probes are used for fluorescent 
detection of only target sequence specific amplification generated during 
PCR. Amplified products are indicated by Threshold Cycle (Ct) in 
 
 
 
amplification curve. The analytical detection limit of the test is 3.8 IU/ml 
(26.6 copies/ml).  
Liver biopsy was performed percutaneously using a 16 G Tru Cut 
needle after attaining an informed consent from patients in group A, B, C 
and D whenever coagulation profile permits. An adequate liver biopsy 
was defined as one in which three or more portal tracts were present. HAI 
Scoring using Modified Ishak’s Scoring for grading and staging of liver 
disease. Two individuals refused to give consent for liver biopsy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 1 : COMPARISON OF HBV DNA 
LEVEL,ALT,AST,GRADE AND STAGE IN CASES WITH 
HBeAg POSITIVE & NEGATIVE: 
 
 
 
 
Factor HBeAg N Mean 
Std. 
Deviation 
Std. Error 
Mean 
P 
HBV DNA 
(copies/ml) 
Positive 10 14910410.00 7102572.426 2246030.611
<0.05
Negative 44* 244983.68 587039.604 88499.550 
AGE 
(in years) 
Positive 10 27.5000 8.61846 2.72539 
>0.05
Negative 63 33.6032 11.79330 1.48582 
ALT 
(IU/ml) 
Positive 10 59.20 27.259 8.620 
<0.05
Negative 63 32.77 13.959 1.759 
AST(IU/ml) 
 
Positive 10 50.9000 24.76310 7.83078 
<0.05
Negative 63 26.4730 10.06055 1.26751 
GRADE** 
 
Positive 10 5.70 1.494 0.473 
<0.05
Negative 29 3.34 0.936 0.174 
STAGE** 
 
Positive 10 2.10 1.101 0.348 
>0.05
Negative 29 0.69 0.761 0.141 
*HBV DNA was Negative i.e. (<26.6 copies/ml) in 19 cases. 
**Liver biopsy was done in 39 cases.                                                                             
 
 
 
TABLE 2: SHOWING NUMBER OF CASES, MEAN AGE, ALT, 
AST, HBV DNA GRADE AND STAGE IN EACH GROUP: 
Group Frequency 
Mean 
ALT 
(IU/ml)
Mean 
AGE 
HBV DNA 
Mean 
(Copies / ml)
Mean 
AST 
(IU/ml) 
Grade Stage 
A 6 80.00 
25.66
67 
16741900.0
0 
68.0000 5.83 2.50 
B 4 28.00 
30.25
00 
12163175.0
0 
25.2500 5.50 1.50 
      C 14 54.54 
32.78
57 
184937.36 41.3714 3.36 0.86 
D 15 26.73 
38.66
7 
543018.27 23.0000 3.69* 0.62 
E 34 26.47 
31.70
59 
2992.33** 21.8706 1.00*** 0*** 
Total 73 36.39 
32.76
71 
2960803.37 29.8192 3.95 1.05 
 
*Liver Biopsy was done in 13 cases of Group D. 
**HBV DNA was Negative i.e. (<26.6 copies/ml) in 19 cases of Group E. 
***Liver biopsy was done in 2 cases of Group E.  
 
 
 
 
 
TABLE 3 : COMPARISON OF ALT, AST, HBV DNA Levels, 
GRADE AND STAGE  
Group ALT(P 
value) 
HBV DNA 
[P value] 
AST [P 
value]  
Grade 
P value 
Stage 
P value 
C&D  P < 0.05  P >0.05 
 
P >0.05 
 
P >0.05 
 
P > 0.05 
 
C&E P <0.05  P<0.05 
 
P >0.05 
 
N/A N/A 
D&E P > 0.05    P < 0.05 
 
P >0.05 
 
N/A N/A 
 
 
 
 
 
 
TABLE 4: COMPARISON OF CASES WITH ELEVATED 
AND NORMAL ALT WITH HBV DNA LEVELS, GRADE, 
STAGE AND AST: 
 
 ALT N 
Mean 
(copies/ml) 
Std. 
Deviation 
(copies/ml) 
Std. Error 
Mean 
(copies/ml) 
 
P 
DNA 
> 40 20 5152026.15 8188966.486 1831108.573
>0.05
< 40 34 1671848.79 4907189.807 841576.109 
GRADE 
> 40 20 4.10 1.518 0.340 
>0.05
< 40 19 3.79 1.512 0.347 
STAGE 
> 40 20 1.35 1.182 0.264 
>0.05
< 40 19 0.74 0.806 0.185 
AST 
(IU/ml) 
> 40 20 49.3600 15.67104 3.50415 
>0.05
< 40 53 22.4453 5.81585 0.79887 
 
 
 
 
TABLE 5: CORELATION OF HBV DNA LEVEL, ALT AND 
AST WITH EACH OTHER AND WITH LIVER HISTOLOGY 
(HAI SCORE): 
FACTOR 
HBV DNA (P 
value) 
ALT (P 
value) 
AST (P 
value) 
GRADE <0.001 >0.05 <0.05 
STAGE <0.001 >0.05 <0.05 
ALT <0.001 - - 
AST <0.001 - - 
DNA - >0.05 <0.05 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
Statistical analyses were carried out using the statistical program 
for social sciences (SPSS). Pearson correlation was carried out. Two 
tailed value of less than 0.05 was considered statistically significant. 
Independent t-test was carried for testing the significance between two 
variables. Results are presented as mean + SD. 
A total of seventy three cases( 57 males and 16 females with mean 
age of 32.84+10.23 years and 32+15.81 years respectively) cases were 
included in the study, as they  could complete the desired protocol .   
In our study Ten cases were  HBeAg positive (13.7%)and HBV 
DNA positive and sixty-three were HBeAg negative (86.3%) individuals 
of whom nineteen  (26 %)cases were HBV DNA negative (<26.6 
copies/ml). There was statistically significant difference in grade, HBV 
DNA levels and ALT but, there was no  significant difference in the stage 
and age between the two groups. 
In our study there were 6 (8.2%) individuals in group A, 4 (5.5%) 
in group B, 14 (19.2%)in group C, 15 (20.5%) in group D and 34(46.6%)  
individuals in group E.  There was no statistically significant difference 
between the Groups C and D in HBV DNA levels, AST, Stage and Grade 
 
 
 
(in Liver biopsy), though there was statistically significant difference in 
ALT levels between the 2 groups. Also there was statistically significant 
difference in ALT levels between cases in Group C and E. There were 
significant difference in DNA levels between group D & group E and 
between group C & group E. Other groups were not tested for their 
statistical significance as there were too few in number. 
HBV DNA levels ranged from <26.6 to 2.5 x 107 copies/ml. 
All the individuals were negative for IgM HBcAg, HIV and anti-
HCV. 
The ALT levels ranged from 14to 85 IU/ml. There were twenty 
cases with elevated ALT i.e. > 40 IU/ml and thirty-four cases with normal 
ALT i.e. <40 IU/ml. There was NO statistically significant difference in 
HBV DNA levels, grade and stage in cases with elevated and normal 
ALT. There was no correlation of ALT with HBV DNA, Grade and 
Stage.  
The AST level ranged from 13 to 92 IU/ml. There was significant 
co-relation of AST with HBV DNA levels, grade and stage of liver 
disease 
 
 
 
HBV DNA levels Co-related significantly with grade i.e. level of 
inflammation in Liver biopsy (r = 0.48, p <0.001) [TABLE 10]. HBV 
DNA levels also co-related statistically with Stage i.e. fibrosis score(r = 
0.47, p <0.001).There was also statistically significant co-relation of ALT 
(r = 0.37, p <0.001) and AST (r = 0.42, p <0.001) with HBV DNA levels. 
There was no correlation between HBV DNA levels with Age of the 
patient. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
 
 
Hepatitis B is an important cause of Acute and chronic liver 
disease in the world. The aim of this study was to determine the 
relationship between biochemical, serological, histological and viral 
replicative indices in an incidentally detected asymptomatic HBsAg 
positive. 
The Natural history of HBsAg carrier is in Asian Countries is 
different from that of the Western Countries. In the west a number of 
studies have demonstrated the benign outcome of HBsAg carries Manno 
et al 4, Reinicke et al 5, Koretz et al 6, Villeneuve et al7, Dragosiscs et al 8, 
de Francis et al 9. This favorable outcome hasn’t been shared by similar 
studies conducted in the Asian region Will et al 10, Hsu et al 11, Beasly et 
al 12, Obata et al 13. 
In the present study there were 10 HBeAg positive constituting 
13.7% of the total study group with a mean age of 27.5+8.62 years and 63 
HBeAg negative individuals constituting 86.3% of the total with a mean 
age of 33.6+11.79 years. Though difference in age was present, similar to 
other studies in which HBeAg negative individuals were older than 
HBeAg positive, the difference was not statistically significant in the 
present study group. This is in discordance with earlier studies by Jie et al 
14 Manesis et al 15, Yuen et al 16, Chan et al 17, who all had demonstrated 
 
 
 
that HBeAg negative cases are older than HBeAg negative.  This may be 
due to the small number of cases in the present study. 
In the present study HBV DNA was negative in 19 patients while 
in the remaining fifty-four cases had HBV DNA ranging from 119 to 2.5 
x 107 copies/ml. The wide variation in HBV DNA levels could be 
explained by that HBV isolates have different genetic subtypes, 
quesispecies, viral mutation and different immune ability to HBV Yao et 
al 18 
In the present study  HBV DNA levels were strongly correlated 
with liver histology in both HBeAg positive and HBeAg negative cases.[ 
With grade r = 0.48, p <0.001 (Significant); stage, r = 0.48, p <0.001 
(significant)].Along with this there was significant  correlation  with ALT 
(r=0.37, p <0.001), and AST (r = 0.42, p <0.001) Mommeja et al 19, Yuen 
et al 20 Iloeje et al.21 But this is in discordance with Huo et al 22, Chandra 
et al 23, Lok et al 24 and Jie et al 14, Kendall et al 25 who all demonstrated 
that, Liver histology was correlated with ALT level and not with HBV 
DNA levels.  
In the present study a correlation was found between HBV DNA 
levels and ALT, AST in both HBeAg positive and HBeAg negative 
individuals. The correlation co-efficient was high. Habersetzer et al 22.  
 
 
 
There was no statistically significant co-relation between Alt levels 
with grade of liver disease.This is in discordance with earlier studies 
which had shown a co-relation between ALT level and grade of liver 
disease, Huo et al 23, Chandra et al 24, Lok et al 25 Kendall et al 26   though 
it is concordance with the newer studies Mommeja-Marin et al 19, Yuen et 
al 20, Iloeje et al.21 .In the present AST levels strongly co-related with 
stage and grade which in concordance with other similar studies. Heo et 
al 27, Borg et al 28. 
Iloeje et al 21 had shown that patients with e-antigen negative 
chronic HBV infection have fluctuating ALT levels and one point 
estimation of ALT may not be reliable.  Keeffe et al 29 showed that 
patients with normal ALT may be associated with significant fibrosis 
especially in patients with a negative chronic HBV infection. ALT 
elevation in chronic hepatitis B patients may occur spontaneous or drug 
induced seroconversions or due to superadded insult with other viruses or 
drug. Perrilo et al 30. With the help of the above mentioned information, it 
is reasonable to conclude that the ALT levels have poor predictability for 
progression of liver disease and planning treatment in patients with CHB. 
 
 
 
In conclusion we can say that HBV DNA levels (PCR) is better in 
determining histological activity and in guiding treatment of 
asymptomatic HBsAg positive individuals than ALT levels. 
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